7 Achieving the best possible outcomessignificant, sustainable weight loss and improved well-beingrequires a partnership between the medication and positive lifestyle changes, particularly concerning diet and exercise
Aspiration can lead to serious complications or death
1,2 Initially developed as antidiabetic treatments, GLP-1 RAs and, more recently, dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists have demonstrated favourable metabolic outcomes with significant and sustainable weight loss in large randomised controlled trials (RCTs) and real-world studies
14 Physicians must navigate the ethical landscape by considering both the potential benefits and the broader societal implications
Meanwhile, the UPLCHR/MS system was used to screen all possible metabolites in the urine, feces and bile, and compared them with blank samples collected before administration